UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 10-Q

[ X ] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~October~~April 3130, ~~2018~~2019

[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

For the transition period from ______ to _______

Commission File Number: 000-55467

APOTHECA BIOSCIENCES, INC.

(Exact name of Registrant as specified in its charter)

Nevada		000-55467		83-0773005
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(I.R.S. Employer Identification Number)

10901 Roosevelt Blvd N Bldg. C 1000
Saint Petersburg, FL 33716

(Address of principal executive offices)

(727) 228-3994

(Registrant's telephone number, including area code)

Cannabis Leaf, Inc.
4500 9^th Ave NE, Seattle WA 98105

(Former name or former address, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

[X]Yes [_]No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). [X]Yes [_]No (Not required)

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer [_] Accelerated Filer [_] Emerging Growth Company [_]

Non-Accelerated Filer [_] Smaller Reporting Company [X]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the exchange act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). [X]No

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Check whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Exchange Act after the distribution of securities under a plan confirmed by a court.

[ ]

YES

[ ]

As of ~~December~~June 1719, ~~2018~~2019, there were ~~114~~179,~~398~~611,~~250~~ 976 shares of the Registrant’s $0.001 par value common stock issued and outstanding.

Special Note Regarding Forward-Looking Statements

Information included in this Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”). This information may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Apotheca Biosciences, Inc. (formerly Cannabis Leaf, Inc.) (the “Company”), to be materially different from future results, performance or achievements expressed or implied by any forward-looking statements. Forward-looking statements, which involve assumptions and describe future plans, strategies and expectations of the Company, are generally identifiable by use of the words “may,” “will,” “should,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. These forward-looking statements are based on assumptions that may be incorrect, and there can be no assurance that these projections included in these forward-looking statements will come to pass. Actual results of the Company could differ materially from those expressed or implied by the forward-looking statements as a result of various factors. Except as required by applicable laws, the Company has no obligation to update publicly any forward-looking statements for any reason, even if new information becomes available or other events occur in the future.

*Please note that throughout this Quarterly Report, and unless otherwise noted, the words "we," "our," "us," the "Company," or "Cannabis" refers to Apotheca Biosciences, Inc.

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION 32 Item 1. Financial Statements 32 Item 2. Management's Discussion and Analysis of Financial Condition or Plan of Operation 163 Item 3. Quantitative and Qualitative Disclosures About Market Risk 186 Item 4. Controls and Procedures 186 PART II - OTHER INFORMATION 197 Item 1. Legal Proceedings 197 Item 1A. Risk Factors 197 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 197 Item 3. Defaults Upon Senior Securities 197 Item 4. Mine Safety Disclosures 197 Item 5. Other Information 197 Item 6. Exhibits 208 SIGNATURES 219

PART I - FINANCIAL INFORMATION

Item 1.

Financial Statements

Unaudited Condensed Consolidated Financial Statements

Apotheca Biosciences, Inc.

Index

		Index
Condensed Consolidated Balance Sheet as of April 30, 2019 (unaudited) and January 31, 2019		F-1
Condensed Consolidated Statement of Operations for the three months ended April 30, 2019 (unaudited) and the period from February 26, 2018, (inception) through to April 30, 2018 (unaudited)		F-2
Condensed Consolidated Statement of cash flows for the three months ended April 30, 2019 (unaudited) and the period from February 26, 2018, (inception) through to April 30, 2018 (unaudited)		F-3
Condensed Statements of stockholders’ deficit for the three months ended April 30, 2019 (unaudited) and the period from February 26, 2018, (inception) through to April 30, 2018 (unaudited)		F-4
Notes to the unaudited condensed consolidated financial statements		F-5

Condensed Consolidated Balance Sheet as of October 31, 2018 (unaudited) and April 30, 2018 (Audited)		F-1
Condensed Consolidated Statement of Operations for the period from February 26, 2018, (inception) through October 31, 2018 (unaudited)		F-2
Condensed Consolidated Statements of Operations for the three months ended October 31, 2018 (unaudited)		F-2
Condensed Consolidated Statement of cash flows for the period from February 26, 2018 (inception) through to October 31, 2018 (Unaudited)		F-3
Notes to the unaudited condensed consolidated financial statements		F-4

APOTHECA BIOSCIENCES, INC.

~~CONDENSED~~ CONSOLIDATED BALANCE ~~SHEET~~SHEETS

	As of			As of
	October 31,			April 30,
	April 30,			January 31,
	2018			2018
	2019 (Unaudited)			2019
	(Unaudited)			(Audited)
ASSETS
Current assets
Cash	$	~~168~~250,~~462~~478		$	-2,942
Deposits and prepaids		6,000			-
Inventory		103,687			7,640
Total Assets	$	174,462		$	1
Deposits and prepaids (including related party rent of $6,000)		6,600			98,302
Total current assets		360,765			108,884
Right to use asset – related party		133,810			-
Equipment, furniture and fixtures (including purchase from related party $2,508) net of accumulated depreciation		7,905			6,441
Intangible assets, net of accumulated amortization		570			-
Total fixed assets, net		142,285			6,441
Total Assets	$	503,050		$	115,325
LIABILITIES AND SHAREHOLDERS’ DEFICIT
Current liabilities
Accounts payable		3427,~~024~~944			~~295~~24,104
Accounts payable – related party		3,724			-
Accounts payable , related party		16,020			8,225
Accrued liabilities		51159,~~053~~281			3082,~~000~~770
Notes payable		18,600			-
Accrued liabilities, related party		5,592			-
Related party advances		-			1,947
Notes payable		18,600			18,600
Derivative liabilities		579,660			-
Related party advances		24,050			-
Convertible note payable, net of discount of $291,687		8,313			-
Derivative liabilities		656,936			771,918
Total liabilities	$	695,374		$	32,242
Lease liability – related party, current portion		108,591			-
Convertible note payable		165,159			26,261
Total current liabilities		1,182,173			931,878
Lease liability – related party, less current portion		30,560			-
Total Liabilities		1,212,733			931,878
Shareholders' Deficit
Common stock: 600,000,000 authorized; $0.001 par value at October 31, 2018 and 200,000,000 authorized, $0.0001 par value at April 30, 2018
Common stock: 600,000,000 authorized; $0.001 par value at April 30, 2019 and 200,000,000 authorized, $0.0001 par value at January 31, 2019
113,914,000 and 111,314,000 shares issued and outstanding at October 31, 2018 and April 30, 2018, respectively		113,914			6,000
118,840,795 and 118,214,000 shares issued and outstanding at April 30, 2019 and January 31, 2019, respectively		118,841			118,214
Additional paid in capital		~~(303~~1,~~187~~596,043	)		-1,503,973
Shares to be issued, common shares		7390,~~700~~544			-73,700
Accumulated deficit		(~~405~~2,~~339~~515,111	)		(382,~~242~~512,440	)
Total Shareholders' Deficit		(~~520~~709,~~912~~683	)		(32816,~~242~~553	)
Total Liabilities and Shareholders' Deficit	$	~~174~~503,~~462~~050		$	-115,325

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

4F-1

APOTHECA BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

	For the three months ended October 31, 2018 (unaudited)			For the period from February 26, 2018 (Inception) through October 31, 2018 (unaudited)
	For the three months ended April 30, 2019 (unaudited)			For the period from February 26, 2018 (inception) through April 30, 2018
Revenues	$	-		$	-
Operating Expenses
Personnel expenses		45112,~~000~~672			~~120~~30,000
General and administrative		110,763			127,984
Marketing and design, related party		24,000			-
Total operating expenses		155,763			247,984
General and administrative		63,540			8,242
Net loss from operations		(155,763	)		(247,984	)
General and administrative, related party		35,268			-
Stock-based compensation		63,600			-
Total operating expenses		299,080			38,242
Net loss from operations		(299,080	)		(38,242	)
Other income (expense):
Interest expense		(971,~~695~~848	)		~~(9,695~~-	)
Gain on settlement of liability		156,000			156,000
Interest expense, related party		(3,092	)		-
Derivative expense		(303,660	)		(303,660	)
Derivative income		371,349			-
Total other income (expense)		~~(157~~296,~~355~~409	)		~~(157,355~~-	)
Net Income	$	(313,118	)	$	(405,339	)
Net loss	$	(2,671	)	$	(38,242	)
Basic and diluted loss per share	$	(0.01	)	$	(0.01	)
Weighted average number of
shares outstanding		~~113~~118,~~769~~243,~~556~~401			7737,~~648~~752,~~826~~809

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

5F-2

APOTHECA BIOSCIENCES, INC.

STATEMENTS OF CHANGES IN SHAREHOLDERS' DEFICIT

	Common Stock
	Shares		Amount		Additional Paid in Capital		Shares to be issued		Accumulated (Deficit)			Total
Balances, February 26, 2018		-	$	-		$ -	$	-	$	-		$	1

Shares issued by Apotheca in exchange for services ($.001 par value)		60,000,000		6,000		-		-		-			6,000

Net loss from February 26, 2018 through April 30, 2018										(38,242	)		(38,242	)

Balances, October 31, 2018		60,000,000	$	6,000		-	$	-	$	(38,242	)	$	(32,242	)

Balances, February 1, 2019		118,214,000	$	118,214	$	1,503,973	$	73,700	$	(2,512,440	)	$	(816,553	)

Beneficial conversion feature		-		-		8,485		-		-			8,485

Shares issued for conversion of debt		178,795		177		12,455		16,844					29,476

Shares issued for compensation		400,000		400		63,200							63,600

Shares issued in satisfaction of accounts payable		50,000		50		7,930							7,980

Net loss for the three months ended April 30, 2019										(2,671	)		(2,671	)

Balances, April 30, 2019		118,840,795	$	118,841	$	1,596,043			$	(2,515,111	)	$	(709,683	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

F-3

APOTHECA BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

	From inception (February 26, 2018) through October 31, 2018 (unaudited)
					For the period
CASH FLOWS FROM OPERATING ACTIVITIES:
					from
Net Loss		$	(405,339	)
					February 26, 2018
Adjustments to reconcile net loss to net cash used by operating activities
		For the three months ended			(inception) through
Change in fair value of derivative liabilities			303,660
		April 30, 2019			April 30, 2018
Stock issued in exchange for services			6,000
		(unaudited)			(Unaudited)
Gain on settlement of liability			(156,000	)
CASH FLOWS FROM OPERATING ACTIVITIES:
Amortization of debt discount			8,313
Net loss		$	(2,671	)	$	(38,242	)
Changes in operating assets and liabilities:
Changes in working capital requirements
Prepaid expenses			(6,000	)
Derivative expense			(371,379	)		-
Accounts payable			34,024
Depreciation and amortization expense			331			-
Accounts payable – related party			3,724
Stock issued for services			63,600			6,000
Accrued liabilities			62,840
Amortization of debt discount			65,227			-
Net Cash Used in Operating Activities			(149,138	)
Increase (decrease) in:
CASH FLOWS FROM FINANCING ACTIVITIES:
Prepaid expenses			91,7034			-
Cash received for subscription agreements			73,700
Inventory			(96,047	)		-
Proceeds from convertible notes payable			243,900
Accounts payable						295
Net Cash Provided in Financing Activities			317,600
Accounts payable - related party			7,795			296
Net increase in cash and cash equivalents			168,462
Related party advances			24,050			1,947
Cash and cash equivalents, beginning of period			-
Accrued expenses			102,255			-
Cash and cash equivalents, end of period		$	168,462
Accrued expenses – related party						30,000
Supplemental disclosure of cash flow information:
Net cash (used in) provided by operating activities			(105,673	)		296
Cash paid for interest		$	-
CASH FLOWS FROM INVESTING ACTIVITIES:
Cash paid for interest
Purchase of furniture and equipment – related party			(1,791	)		-
Supplemental disclosure of non-cash financing activities:
Net cash used in investing activities			(1,791	)		-
Shares issued to settle a liability		$	1,144,000
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from convertible notes payable			355,000			-
Net cash provided by financing activities			355,000
NET INCREASE IN CASH			247,536			296
CASH, BEGINNING OF PERIOD			2,942			-
CASH, END OF PERIOD		$	250,478		$	296
Supplemental disclosure of cash flow information:
Cash paid for interest expense		$	-		$	-
Cash paid for income taxes		$	-		$	-
Noncash operating and financing activities:		$	-		$	-
Beneficial conversion feature on convertible notes payable		$	8,485		$	-
Stock issued in satisfaction of accounts payable		$	7,980		$	-

The accompanying notes are an integral part of these unaudited ~~condensed~~ ~~consolidated~~condensed financial statements

6F-4

APOTHECA BIOSCIENCES, INC.

NOTES TO THE ~~UNAUDITED~~ CONDENSED CONSOLIDATED ~~FINANCIAL~~ FINANCIAL STATEMENTS

FOR THE ~~PERIOD FROM~~THREE ~~FEBRUARY~~MONTHS ~~26,~~ENDED ~~2018,~~APRIL ~~(INCEPTION) THROUGH OCTOBER 31~~30, ~~2018~~ 2019

NOTE 1 -ORGANIZATION AND BASIS OF PRESENTATION

Apotheca Biosciences is a medical device company developing engineering and device solutions for cannabinoid medical technologies. The company is incorporated in Nevada as a Corporation with principal business in Saint Petersburg, FL. The company develops, license and market cannabinoid technologies to various market sectors.

Apotheca Biosciences is developing cutting-edge medical products, nutraceuticals, formulation and delivery technologies for the healthcare and consumer care industry. Our pipeline of products includes, transdermal, sublingual, and nasal delivery technologies for precise and controlled dosing of cannabinoids. We believe that we can deliver meaningful benefits using our technologies to the world’s aging population.

The last two decades of research have brought a tremendous improvement in knowledge of the endocannabinoid system (eCB system) components and functions under physiological and pathological conditions. The eCB is a neuromodulatory system consists of two subtypes of cannabinoid receptors, CB1 and CB2

Vision

Apotheca Biosciences is positioning to be global leader in discovering new cannabinoid medical technologies to make life better and healthier

Mission

To contribute to human welfare through innovative biomedical engineering solutions; to deliver cannabinoid actives that relieve pain, restore health, and longevity of millions of patients around the world.

Core values:

Bring cost-effective and meaningful medical care to patients

Build an environment of creativity and transform new ideas into breakthrough technologies and devices

Pursue innovative engineering solutions that challenge established thinking

Change and act with speed via scientific collaboration, partnership and a winning spirit

Apotheca Biosciences, Inc. (the "Company") was originally incorporated in the State of Nevada on October 6, 2014, under the name Pacificorp Holdings, Ltd. On June 2, 2017 the Company entered into a short form Merger Agreement with the Company’s wholly owned subsidiary in order to effect the change of their corporate name. The name change was effected through a parent/subsidiary short-form merger of the Company and its wholly-owned subsidiary, Cannabis Leaf Incorporated., a Nevada Corporation (the “Subsidiary”), under Section 92A.180 of the Nevada Revised Statutes (“NRS”). Pursuant to an Agreement of Merger, dated June 2, 2017, between the Company and the Subsidiary, effective June 7, 2017, the Subsidiary merged with and into the Company and ceased to exist (the “Merger”). Pacificorp Holdings, Ltd was the surviving entity and adopted the name of the subsidiary, Cannabis Leaf Incorporated.

On March 6, 2018 an Agreement and Plan of Merger (the "Agreement") was made and entered into as of March 6, 2018 by and among Cannabis Leaf Incorporated (“CLI”) and Apotheca. The respective Boards of Directors of CLI and Apotheca determined that it was in the best interest of each company and its respective stockholders to consummate the business combination transaction provided for in the agreement in which Apotheca would merge with and into CLI (the "Merger"), with Apotheca as the surviving entity post-Merger, the respective Boards of Directors of CLI and the Apotheca approved the Agreement, the Merger, and the other transactions contemplated by the Agreement, upon the terms and subject to the conditions set forth in the Agreement in accordance with the Nevada Revised Statutes regarding business combinations or merger ("NRS"), and their respective corporate documents.

7F-5

APOTHECA BIOSCIENCES, INC.

NOTES TO THE ~~UNAUDITED~~ CONDENSED CONSOLIDATED ~~FINANCIAL~~ FINANCIAL STATEMENTS

FOR THE ~~PERIOD FROM~~THREE ~~FEBRUARY~~MONTHS ~~26,~~ENDED ~~2018,~~APRIL ~~(INCEPTION) THROUGH OCTOBER 31~~30, ~~2018~~ 2019

NOTE 1 -ORGANIZATION AND BASIS OF PRESENTATION (CONTINUED)

On August 2, 2018, Articles of Merger and the Merger Agreement were filed with the Nevada Secretary of State, giving Effect to the Merger and the change of name of our company to Apotheca Biosciences Incorporated.

These financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States and are expressed in United States (US) dollars. The Company has not produced any revenue from its principal business and is a development stage company. The Company has changed it business from a license holder with Affordable Green LLC of Tacoma WA to a cannabis bioscience company. Additionally, the Company has changed its name as a result of a merger with the Company’s wholly owned subsidiary Apotheca Biosciences, Inc. as a result of this merger Cannabis Leaf adopted the name of the subsidiary. The comparative balance sheet is the balance sheet audited as of April 30, 2018 for Apotheca Private.

NOTE 2 -SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The ~~unaudited~~Financial ~~condensed~~Statements ~~financial statements of the Company~~ and ~~the~~related ~~accompanying~~disclosures have ~~notes~~been ~~included~~prepared inpursuant ~~this~~to ~~Quarterly~~the ~~Report~~rules onand ~~Form~~regulations ~~10-Q~~of ~~are~~the ~~unaudited~~Securities and ~~have~~Exchange ~~not~~Commission ~~been reviewed~~(“SEC”). In ~~the~~The ~~opinion of management, all adjustments necessary for a fair presentation of the Condensed~~ Financial Statements have been ~~included.~~ ~~Such~~prepared ~~adjustments~~using ~~are of a normal, recurring nature. The Condensed Consolidated Financial Statements, and~~ the ~~accompanying notes,~~accrual ~~are~~basis ~~prepared~~of accounting in accordance with ~~generally accepted~~ accounting principles generally accepted in the United States of America ("“GAAP"”). ~~Results for~~and ~~the interim periods~~ presented ~~are~~in ~~not~~US ~~necessarily~~dollars. ~~indicative~~The offiscal ~~the~~year ~~results~~end ~~that~~is ~~might~~January ~~be expected for the entire fiscal year~~31.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.

Cash and Cash Equivalents

For the purpose of the statement of cash flows, cash equivalents include time deposits, certificate of deposits, and all highly-liquid debt instruments with original maturities of three months or less.

Inventory

Inventory is valued at the lower of the inventory’s cost or the current market price of the inventory. Management compares the cost of inventory with its market value and an allowance is made to write down inventory to market value, if lower. At April 30, 2019 and January 31, 2019, the balance of inventory was $103,687 and $7,640, respectively.

Fair Value of Financial Instruments

The Company’s financial instruments consist primarily of accounts payable and accrued liabilities and loans payable – related parties. The carrying amounts of such financial instruments approximate their respective estimated fair value due to the short-term maturities and approximate market interest rates of these instruments.

Basic and Diluted Earnings Per Share

Net loss per share is calculated in accordance with FASB ASC 260, Earnings Per Share, for the period presented. ASC 260 requires presentation of basic earnings per share and diluted earnings per share. Basic income (loss) per share (“Basic EPS”) is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share (“Diluted EPS”) is similarly calculated. Dilution is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. ~~For~~These potentially dilutive securities were not included in the calculation of loss per common share for the period ended ~~October~~April 3130, ~~2018, there~~2019 ~~were~~and noJanuary ~~potentially~~31, ~~dilutive~~2019 ~~securities~~because their effect would be anti-dilutive.

8 The outstanding securities consist of the following:


	April 30, 2019		January 31, 2019
Potentially dilutive options		1,198,289		1,198,289
Potentially dilutive warrants		1,170,000		720,000
Potentially dilutive convertible debt		6,546,616		3,056,616
		7,716,616		4,974,905

F-6

APOTHECA BIOSCIENCES, INC.

NOTES TO THE ~~UNAUDITED~~ CONDENSED CONSOLIDATED ~~FINANCIAL~~ FINANCIAL STATEMENTS

FOR THE ~~PERIOD FROM~~THREE ~~FEBRUARY~~MONTHS ~~26,~~ENDED ~~2018,~~APRIL ~~(INCEPTION) THROUGH OCTOBER 31~~30, ~~2018~~ 2019

NOTE 2 -SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

New Accounting Pronouncements

In ~~February~~June ~~2016~~2018, the FASB issued ~~ASC~~Accounting ~~842 that~~Standards ~~requires~~Update ~~lessees~~(“ASU”) toASU ~~recognize~~2018-07, Stock ~~lease~~Compensation ~~assets~~(Topic ~~and~~718): ~~corresponding~~Improvements ~~lease~~to ~~liabilities~~Nonemployee onShare-Based Payment Accounting, which simplifies the ~~balance~~accounting ~~sheet~~for share-based payments granted to nonemployees for ~~all~~goods ~~leases~~and ~~with~~services ~~terms~~and ofaligns ~~more~~most ~~than~~of 12the ~~months.~~guidance ~~The~~on ~~update,~~such ~~which~~payments ~~supersedes~~to ~~existing~~nonemployees ~~lease~~with ~~guidance,~~the ~~will~~requirements ~~continue~~for share-based payments granted to ~~classify~~employees. ~~leases~~ASU 2018-07 asis ~~either~~effective ~~finance~~on ~~or operating~~January 1, ~~with~~2019. ~~the~~Early ~~classification~~adoption ~~determining~~is ~~the~~permitted. ~~pattern~~The adoption of ~~expense~~this ~~recognition~~ASU indid not have a material impact on the ~~income~~Company’s ~~statement~~consolidated financial statements.

~~The~~In October 2016, the FASB issued ASU ~~will~~2016-16, Income Taxes be(Topic 740): ~~effective~~Intra-Entity ~~for~~Transfer ~~annual~~of ~~and~~Assets ~~interim~~Other than Inventory, which requires the recognition of the income ~~periods~~tax ~~beginning~~consequences ~~January~~of 1an intra-entity transfer of an asset, ~~2019~~other than inventory, ~~with~~when ~~early~~the ~~adoption~~transfer ~~permitted,~~occurs. ~~and~~ASU 2016-16 is ~~applicable~~effective for oninterim aand ~~modified~~annual ~~retrospective~~periods ~~basis~~beginning after December 15, 2018, with ~~various optional~~early ~~practical~~adoption ~~expedients~~permitted. The ~~Company~~adoption isof ~~assessing~~this ~~the~~ASU did not have a material impact ofon ~~this~~the ~~standard~~Company’s consolidated financial statements.

In ~~May~~February ~~2014~~2016, the FASB issued ASU ~~2014~~2016-0902, Leases ~~was~~(Topic ~~issued~~842). ~~related~~ ASU 2016-02 requires lessees to ~~revenue~~recognize ~~from~~lease ~~contracts~~assets ~~with~~and ~~customers.~~lease ~~The~~liabilities ~~ASU~~on ~~was~~the ~~further~~balance ~~amended~~sheet inand ~~August~~requires expanded ~~2015,~~disclosures ~~March~~about ~~2016,~~leasing ~~April~~arrangements. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 and interim ~~May~~periods ~~2016~~in byfiscal ~~ASU 2015-14~~years beginning after December 15, ~~2016-08~~2018, ~~2016-10~~with ~~and~~early ~~2016-12~~adoption permitted. The Company adopted this standard on February 1, 2019.

The Company reviews new ~~standard~~accounting ~~provides~~standards as aissued. ~~five-step~~No ~~approach~~new standards had any material effect on these financial statements. The accounting pronouncements issued subsequent to bethe ~~applied~~date toof ~~all~~these ~~contracts~~financial ~~with~~statements ~~customers~~that were considered significant by management were evaluated for the potential effect on these consolidated financial statements. Management does not believe any of the subsequent pronouncements will have a material effect on these consolidated financial statements as presented and ~~also~~does ~~requires~~not ~~expanded~~anticipate ~~disclosures~~the ~~about~~need ~~revenue~~for ~~recognition~~any future restatement of these consolidated financial statements because of the retro-active application of any accounting pronouncements issued subsequent to April 30, 2018 through the date these financial statements were issued.

In August 2015, the effective date was deferred to reporting periods, including interim periods, beginning after December 31, 2017, and will be applied retrospectively. Early adoption is not permitted.

The Company reviews new accounting standards as issued. No new standards had any material effect on these financial statements. The accounting pronouncements issued subsequent to the date of these financial statements that were considered significant by management were evaluated for the potential effect on these consolidated financial statements. Management does not believe any of the subsequent pronouncements will have a material effect on these consolidated financial statements as presented and does not anticipate the need for any future restatement of these consolidated financial statements because of the retro-active application of any accounting pronouncements issued subsequent to October 31, 2018 through the date these financial statements were issued.

NOTE 3 – MERGER

On March 6, 2018 an Agreement and Plan of Merger was made and entered into as of March 6, 2018 by and among Cannabis Leaf (CLI) and Apotheca. The respective Boards of Directors of CLI and Apotheca have determined that it is in the best interest of each company and its respective stockholders to consummate the business combination transaction provided for in the agreement in which Apotheca would merge with and into CLI , with Apotheca (post name change from cannabis Leaf) as the surviving entity post-Merger, upon the terms and subject to the conditions set forth herein; the respective Boards of Directors of CLI and the Apotheca have approved the Agreement, the Merger, and the other transactions contemplated by the Agreement, upon the terms and subject to the conditions set forth in the Agreement in accordance with the Nevada Revised Statutes regarding business combinations or merger ("NRS"), and their respective corporate documents.

At the Effective Time, by virtue of the Merger and without any action on the part of CLI or Apotheca or any holder of capital stock of CLI or Apotheca:

(a) Capital Stock of CLI. Each issued and outstanding share of capital stock of shall by virtue of the Merger and without any action on the part of any holder thereof, be converted into and shall be existing as one share of CLI's common stock without need of re-issuance. Such shares shall thereafter constitute all of the issued and outstanding capital stock of the Surviving Corporation being Apotheca.

(b) Conversion of CLI Stock:(i) Each share of CLI Common Stock issued and outstanding immediately prior to the Effective Time (individually a "Share" and collectively the "Shares"), shall be considered shares of Apotheca as the surviving entity as set forth below (the "Merger Consideration").F-7

APOTHECA BIOSCIENCES, INC.

NOTES TO THE ~~UNAUDITED~~ CONDENSED CONSOLIDATED ~~FINANCIAL~~ FINANCIAL STATEMENTS

FOR THE ~~PERIOD FROM~~THREE ~~FEBRUARY~~MONTHS ~~26,~~ENDED ~~2018,~~APRIL ~~(INCEPTION) THROUGH OCTOBER 31~~30, ~~2018~~ 2019

~~NOTE~~(b) 3Conversion –of ~~MERGER~~CLI Stock:(~~CONTINUED~~i) Each share of CLI Common Stock issued and outstanding immediately prior to the Effective Time (individually a "Share" and collectively the "Shares"), shall be considered shares of Apotheca as the surviving entity as set forth below (the "Merger Consideration").

(ii) At the Effective Time, each Share held by CLI as treasury stock or held by CLI, or any Subsidiary of CLI, immediately prior to the Effective Time shall, by virtue of the Merger and without any action on the part of CLI continue to exist as shares of Apotheca as the surviving entity without further consideration with respect thereto.

(iii) At the Effective Time, each Share of the Treasury Stock as Authorized Shares but unissued Shares of CLI shall become Treasury Shares but unissued Shares of Apotheca, with no change the authorized shares which were in effect immediately prior to the Effective Time.

(iv) At the Effective Time, Apotheca as the surviving entity and in exchange for the acquisition of Apotheca shall be issued as such exchange for control and merger the amount of sixty million (60,000,000) shares of Apotheca as the surviving Company in the form of common shares to be distributed as set forth by Apotheca at its direction on a schedule set forth for issuance. Such shares shall be considered the Merger Control Shares and shall represent approximately sixty percent of the then post-issuance control of CLI post-merger. (v) At the time of exchange in such transaction, there is as certified by CLI, its board of directors and management, exist no convertible or other debt with claims or rights superior for the issuance of any shares of common stock in CLI, and no such claims need be recognized by Apotheca as debt of the surviving entity. Any such debt must have been and was not disclosed to Apotheca before this transaction, and the existing of such debt or claims is a liability of the prior management of CLI and not of Apotheca as the surviving entity.

Closing. Upon the terms and subject to the conditions set forth herein and unless this Agreement has been terminated pursuant to its terms, the closing of the Merger on May 15, 2018 at which time the conditions to Closing set forth in this Agreement shall have been satisfied or, to the extent permitted hereunder, waived by the appropriate party (other than those conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction or, to the extent permitted hereunder, waiver of all such conditions) or at such other time, date or location as the parties hereto agree. The date on which the Closing actually occurs, and the transactions contemplated hereby become effective is hereinafter referred to as the Closing Date CLI and Apotheca shall deliver the certificates and other documents and instruments required to be delivered hereunder.

Effective Time of the Merger. Subject to ~~the~~ the provisions of this Agreement, at the Closing, the parties hereto shall (a) cause a certificate of merger in substantially the ~~form~~ form required by the Secretary of State of Nevada to be executed and filed with the Secretary of State of the State of Nevada, and (b) take all such other and further actions as may be required by the NRS or other applicable Law to make the Merger effective. ~~The~~ The Merger shall become effective as of the date and time of the filing of the Nevada Certificate of Merger or at such later date or or time as may be agreed by CLI and CLI in writing and specified in the Nevada Certificate of Merger in accordance with relevant ~~provisions~~ provisions of the NRS. The date and time of such effectiveness are referred to herein as the Effective Time.

F-8

APOTHECA BIOSCIENCES, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED APRIL 30, 2019

On August 2, 2018, Articles of Merger and the Merger Agreement were filed with the Nevada Secretary of State, giving Effect to the Merger and the change of name of our company to Apotheca Biosciences Incorporated.

The unaudited pro forma combined condensed financial statements were prepared using the acquisition method of accounting as outlined in Financial Accounting Standards Board Accounting Standards Codification (“ASC”) 805, Business Combinations, with the Company considered the acquiring company. Based on the acquisition method of accounting, the consideration transferred by the Company is based on number or equity interests (e.g., shares) the Company issued to give the shareholders of the CLI the same percentage of equity interest in the combined entity that resulted from the reverse merger. Consolidated statements immediately following the reverse merger are a continuation of the financial statements of the Company (“accounting acquirer”) retroactively adjusted to reflect the CLI (“accounting acquiree”) legal capital.

APOTHECA BIOSCIENCES, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE PERIOD FROM FEBRUARY 26, 2018, (INCEPTION) THROUGH OCTOBER 31, 2018

NOTE 3 – MERGER (CONTINUED)

The acquisition of a private operating company by a nonoperating public shell corporation typically results in the owners and management of the private company having actual or effective voting and operating control of the combined company. A public shell reverse acquisition is viewed as a capital transaction in substance, rather than a business combination. As a result, it should be accounted for as a reverse recapitalization equivalent to the issuance of stock by the private company for the net monetary assets of the shell corporation accompanied by a recapitalization. This accounting treatment is similar to that resulting from a reverse acquisition, except that no goodwill or other intangible assets should be recorded.

The following is the statement of stockholders’ equity as of October 31, 2018 reflecting the recapitalization.

APOTHECA BIOSCIENCES, INC.

Unaudited Pro Forma Condensed Consolidated Statement of Stockholders’ Equity for the Period

From February 26, 2018 (Inception) through to October 31, 2018

	Shares		Amount		Additional Paid in Capital			Shares to be issued		Accumulated (Deficit)		Total
Balances, February 26, 2018		-	$	-	$	-		$	-	$	-	$	-
Shares issued by Apotheca in exchange for services ($.001 par value)		60,000,000		6,000		-			-		-		6,000
Recapitalization on August 2, 2018		51,314,000		105,314		(1,444,587	)						(1,339,273	)
Shares issued in satisfaction of accrued liability (license settlement)		2,600,000		2,600		1,141,000							1,144,000
Shares to be issued									73,700				73,700
Net loss from February 26, 2018 through October 31, 2018											405,339		405,339
Balances, October 31, 2018		113,914,000	$	113,914	$	(303,187	)	$	73,7000	$	405,339	$	(520,912	)

APOTHECA BIOSCIENCES, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE PERIOD FROM FEBRUARY 26, 2018, (INCEPTION) THROUGH OCTOBER 31, 2018

NOTE 4 – GOING CONCERN

The Company's financial statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. At ~~October~~ 31April 30, 2019 ~~2018~~ and ~~April~~January 3031, ~~2018~~2019, the Company had $~~168~~250,~~462~~478 and $02,942 in cash and $~~520~~818,~~912~~908 and $32822,~~242~~994 in negative working capital, respectively. ~~From~~For the three months ended April 30, 2019 and from inception (February 26, 2018) through ~~October~~April 3130, 2018, the Company had a net loss of $~~405~~171 and $38,~~339~~242, respectively. Continued losses may adversely affect the liquidity of the Company in the future. Therefore, ~~the~~ the factors noted above raise substantial doubt about our ability to continue as a going concern. The recoverability of of a major portion of the recorded asset amounts shown in the accompanying balance sheet is dependent upon continued operations of of the Company, which in turn is dependent upon the Company's ability to raise additional capital, obtain financing and to succeed in its future operations. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s existence is dependent upon management’s ability to develop profitable operations and resolve its liquidity problems.

NOTE 5 – ~~ACCOUNTS PAYABLE – RELATED PARTY~~INVENTORY

As of ~~October~~April 3130, ~~2018,~~2019 ~~the~~and ~~Company~~January ~~has~~31, an2019, ~~accounts~~the ~~payable~~ balance ofin inventory is $3103,~~724~~687 toand a$7,640, ~~related party~~respectively. The ~~Company~~inventory ~~has~~consists aof ~~lease~~$7,640 ~~agreement~~in ~~with~~ the ~~related~~raw ~~party,~~material ~~Nuvus~~CBD ~~Gro Corp~~Isolate, in which ~~the~~is ~~Company~~a ~~pays $6~~pure,~~408~~ ~~per~~crystalline powder that ~~month~~contains ~~for~~99% ~~office~~pure CBD ~~space.~~and ~~On October 15~~$96,047 ~~2018,~~of ~~the~~finished ~~Company~~CBD ~~paid~~products ~~$2,684~~((i.e. ~~towards the $6~~oils,~~408 rent~~ ~~due~~drops, ~~for~~- ~~October~~gel ~~leaving a balance of $3~~caps,~~724.~~ ~~See~~and ~~Note~~sleep 10caps).

~~NOTE 6 – ACCRUED LIABILITIES~~F-9

As of October 31, 2018, the Company has the following accrued liabilities:

	Amount
Accrued salary – officer	$	38,791
Credit card		9,608
Accrued interest		2,654
Total	$	51,053

NOTE 7 – NOTES PAYABLE

As of October 31, 2018, the Company had outstanding notes payable totaling $18,600. The notes bear an interest rate of 5% per annum and are due upon demand giving 30 days written notice to the borrower. From inception through October 31, 2018, the Company recorded $464 in interest expense on the notes.

NOTE 8 – GAIN ON SETTLEMENT OF LIABILITY

In May 2017, CLI, the accounting acquiree, entered into a Licensing Agreement with Affordable Green Washington LLC where the consideration was $2,100,000. On May 3, 2018 the CLI entered into a Settlement and Release Agreement with AGH WA, LLC in order to terminate the License Agreement and cease the business relationship between the Parties and remedy any defaults of the terms and conditions of the License Agreement. The Compensation and Settlement pertaining to entering into the Settlement and Release Agreement was an aggregate total of 2,600,000 restricted Common Shares. On CLI’s balance sheet, a liability was recorded in the amount of $2,158,000, which was based on a fair value of $0.83 per share on the commitment date. As of the merger date, the liability balance of $1,300,000 was assumed by Apotheca in the merger. On August 7, 2018, Apotheca issued 2,600,000 in full satisfaction of the liability. On the date the shares were issued, the fair value of the shares were equal to $0.44. As a result, Apotheca recorded a gain on settlement of liability of $156,000.

APOTHECA BIOSCIENCES, INC.

NOTES TO THE ~~UNAUDITED~~ CONDENSED CONSOLIDATED ~~FINANCIAL~~ FINANCIAL STATEMENTS

FOR THE ~~PERIOD FROM~~THREE ~~FEBRUARY~~MONTHS ~~26,~~ENDED ~~2018,~~APRIL ~~(INCEPTION) THROUGH OCTOBER 31~~30, ~~2018~~2019

NOTE 96 – ~~CONVERTIBLE~~PREPAID ~~NOTE PAYABLE~~ASSETS

OnAs October 3, 2018, the Company entered into a Securities Purchase Agreement with Firstfire Global Opportunities Fund, LLC, an accredited investor “Firstfire” pursuant to which the Company issued to Firstfire a Senior Convertible Promissory Note (“Note”) in the aggregate principal amount of ~~$300,000.~~April ~~The Note The Company received net proceeds of $243~~30,~~900~~ ~~after~~2019 ~~a $24,000 original note discount~~ and ~~$32,100~~January ~~of financing costs. The Note has a maturity date of October 3~~31, 2019 ~~and~~ , the Company has ~~agreed to pay interest on~~ the ~~unpaid~~following principal balance of the Note at the rate of five percent (5%) per annum from the date on which the Note is issued until the same becomes due and payable, whether at maturity or upon acceleration or by prepayment or otherwise. The Company shall have the right to prepay the Note, provided it makes a payment to Firstfire as set forth in ~~the~~prepaid ~~Note.~~assets:

	April 30,		January 31,
	2019		2019

Prepaid inventory	$	-	$	88,602
Prepaid rent, related party		6,000		6,000
Prepaid services		600		3,700
	$	6,600	$	98,302

Note:

At January 31, 2019, the prepaid inventory balance of $88,602 consisted of a down payment for 50% of a finished CBD products (i.e. oils, drops, - gel caps, and sleep caps). That inventory has since been received.

The prepaid rent consists of the last month’s rent deposit in the amount of $6,000. The rent was paid to a related party. See Note 16.

The prepaid services consist of monies paid to a consultant.

NOTE 7 – PROPERTY AND EQUIPMENT

Property and equipment, net, consisted of the following at April 30, 2019 and January 31, 2019:

	April 30,			January 31,
	2019			2019

Computer equipment	$	5,906		$	4,115
Furniture and fixtures		2,508			2,508
		8,414			6,623
Less: accumulated depreciation		(509	)		(182	)
	$	7,905		$	6,441

The Company purchased nine cubicles and nine office chairs amounting to $2,508 from Nuvus Gro Corp, which is a related party. This is classified in furniture and fixtures. Depreciation expense related to these assets for the three months ended April 30, 2019 amounted to $327.

F-10

APOTHECA BIOSCIENCES, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED APRIL 30, 2019

NOTE 8 – INTANGIBLE ASSETS

Intangible assets, net, consisted of the following at April 30, 2019 and January 31, 2019:

	April 30,			January 31,
	2019			2019

Trademarks	$	575		$	-
Less: accumulated amortization		(5	)		-
	$	570		$	-

Amortization expense related to these assets for the three months ended April 30, 2019 amounted to $5.

NOTE 9 – ACCRUED LIABILITIES

As of April 30, 2019 and January 31, 2019, the Company has the following accrued liabilities:

	April 30, 2019	January 31, 2019
Accrued salary – officer	$ 132,395	$ 57,610
Payroll liabilities	11,293	6,256
Credit card	-	9,765
Accrued interest	15,593	9,139
Total	$ 159,281	$ 82,770

As of April 30, 2019 and January 31, 2019, the Company has the following accrued liabilities to related parties:

	April 30, 2019	January 31, 2019
Accrued liability, related party	$ 5,592	$ -
Total	$ 5,592	$ -

NOTE 10 – NOTES PAYABLE

As of April 30, 2019, the Company had outstanding notes payable totaling $18,600. The notes bear an interest rate of 5% per annum and are due upon demand giving 30 days written notice to the borrower. For the three months ended April 30, 2019, the Company recorded $232 in interest expense on the notes.

NOTE 11 – CONVERTIBLE NOTE PAYABLE

October 3, 2018 Note – Firstfire Global Opportunities Fund, LLC

On October 3, 2018, the Company entered into a Securities Purchase Agreement with Firstfire Global Opportunities Fund, LLC, an accredited investor “Firstfire” pursuant to which the Company issued to Firstfire a Senior Convertible Promissory Note (“Note 1”) in the aggregate principal amount of $300,000. The Company received net proceeds of $243,900 after a $24,000 original note discount and $32,100 of financing costs. The Note has a maturity date of October 3, 2019 and the Company has agreed to pay interest on the unpaid principal balance of the Note at the rate of five percent (5%) per annum from the date on which the Note is issued until the same becomes due and payable, whether at maturity or upon acceleration or by prepayment or otherwise. The Company shall have the right to prepay the Note, provided it makes a payment to Firstfire as set forth in the Note.

The outstanding principal amount of the Note is convertible into common stock at the lender’s option at $0.20 per share. The agreements contain down-round protection in the event the Company issues common stock at a lower price. In connection with the agreement, the Company issued detachable warrants to purchase 480,000 shares of the company’s common stock. The warrants have a strike price of $0.3125 and an expiration date of October 3, 2021. The warrants contain down-round protection in the event the Company issues common stock at a lower price.

F-11

APOTHECA BIOSCIENCES, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED APRIL 30, 2019

Accounting Considerations

The Company has accounted for the Note as a financing transaction, wherein the net proceeds that were received were allocated to the financial instrument issued. Prior to making the accounting allocation, the Company evaluated the agreement under ASC 815 Derivatives and Hedging (“ASC 815”). ASC 815 generally requires the analysis embedded terms and features that have characteristics of derivatives to be evaluated for bifurcation and separate accounting in instances where their economic risks and characteristics are not clearly and closely related to the risks of the host contract. The material embedded derivative features consisted of the embedded conversion option and default puts. The conversion option and default puts bear risks of equity which were not clearly and closely related to the host debt agreement and required bifurcation. Current accounting principles that are also provided in ASC 815 do not permit an issuer to account separately for individual derivative terms and features that require bifurcation and liability classification. Rather, such terms and features must be and were bundled together and fair valued as a single, compound embedded derivative. Additionally the warrants required classification as derivative liabilities.

Based on the previous conclusions, the Company allocated the cash proceeds first to the derivative components at its fair value with the residual allocated to the host debt contract, as follows:

	Allocation	~~Allocation~~
Compound embedded derivative	$ 408,373	$	~~408,373~~
Derivative warrants	128,544		~~128,544~~
Day-one derivative loss	(260,917)		~~(260,917~~	)
Financing fees	(32,100)		~~(32,100~~	)
Net proceeds	$ (243,900)	$	~~(243,900~~	)

The net proceeds of $243,900 were allocated to the compound embedded derivative and derivative warrants. This resulted in a day-one derivative loss of $260,917. Due to the 100% discount of the note, the net carrying value on the balance sheet was zero upon inception. The Note will be amortized up to its face value of $300,000 over the life of Note based on an effective interest rate. Amortization expense for the period amounted to $836,~~313~~674. During the three months ended April 30, 2019, the holder converted $35,000 in principal into 481,310 shares of common stock. The carrying value of the Note as of ~~October~~April 30, 2019 and January 31, ~~2018~~2019 amounted to $851,~~313~~921 and $22,104, respectively. The remaining principal balance as of April 30, 2019 is $265,000. The note will be amortized up to the face value over the remaining life of the note.

~~NOTE~~January 1018, 2019 Note –~~DERIVATIVE~~ ~~FINANCIAL~~Firstfire Global ~~INSTRUMENTS~~Opportunities Fund, LLC

~~The~~On ~~following~~January ~~tables~~18, ~~summarize~~2019, the ~~components~~Company entered into ofa Securities Purchase Agreement with Firstfire Global Opportunities Fund, LLC, an accredited investor “Firstfire” pursuant to which the Company’s ~~derivative~~issued ~~liabilities~~to Firstfire a Senior Convertible Promissory Note (“Note 2”) in the aggregate principal amount of $150,000. The Company received net proceeds of $124,200 after a $12,000 original note discount and ~~linked~~$13,800 ~~common~~of ~~shares~~financing costs. asThe Note has a maturity date of ~~October~~January 3118, ~~2018~~2020 and the ~~amounts~~Company ~~that~~has ~~were~~agreed ~~reflected~~to pay interest on the unpaid principal balance inof ~~income~~the ~~related~~Note toat ~~derivatives~~the ~~for~~rate of five percent (5%) per annum from the ~~period~~date ~~ended:~~on which the Note is issued until the same becomes due and payable, whether at maturity or upon acceleration or by prepayment or otherwise. The Company shall have the right to prepay the Note, provided it makes a payment to Firstfire as set forth in the Note.

	October 31, 2018
The financings giving rise to derivative financial instruments	Indexed Shares	Fair Values
Compound embedded derivative	301,898	$ (439,548)
Derivative warrants	480,000	(140,112)
Total	781,898	$ (579,660)

The outstanding principal amount of the Note is convertible into common stock at the lender’s option at $0.20 per share. The agreements contain down-round protection in the event the Company issues common stock at a lower price. In connection with the agreement, the Company issued detachable warrants to purchase 240,000 shares of the company’s common stock. The warrants have a strike price of $0.3125 and an expiration date of January 18, 2022. The warrants contain down-round protection in the event the Company issues common stock at a lower price.

13F-12

APOTHECA BIOSCIENCES, INC.

NOTES TO THE ~~UNAUDITED~~ CONDENSED CONSOLIDATED ~~FINANCIAL~~ FINANCIAL STATEMENTS

FOR THE ~~PERIOD FROM~~THREE ~~FEBRUARY~~MONTHS ~~26,~~ENDED ~~2018,~~APRIL ~~(INCEPTION) THROUGH OCTOBER 31~~30, ~~2018~~ 2019

~~NOTE~~Accounting ~~10 –DERIVATIVE FINANCIAL INSTRUMENTS (CONTINUED)~~Considerations

The ~~following~~Company ~~table~~has ~~summarizes~~accounted for the ~~effects~~Note onas a financing transaction, wherein the ~~Company’s~~net proceeds that were received were allocated to the financial instrument issued. Prior to ~~gain~~making the accounting allocation, the Company evaluated the agreement under ASC 815 Derivatives and Hedging (~~loss~~“ASC 815”). ~~associated~~ASC ~~with~~815 ~~changes~~generally inrequires the ~~fair~~analysis ~~values~~embedded terms and features that have characteristics of derivatives to be evaluated for bifurcation and separate accounting in instances where their economic risks and characteristics are not clearly and closely related to the risks of the host contract. The material embedded derivative ~~financial~~features ~~instruments~~consisted byof ~~type~~the embedded conversion option and default puts. The conversion option and default puts bear risks of ~~financing~~equity ~~for~~which ~~the~~were ~~three~~not clearly and closely related ~~months~~to ~~ended~~the ~~October~~host ~~31,~~debt ~~2018~~agreement and required bifurcation. Current accounting principles that are also provided in ASC 815 do not permit an issuer to account separately for ~~the~~individual ~~period~~derivative ~~from~~terms ~~February~~and 26features that require bifurcation and liability classification. Rather, ~~2018~~such ~~(Inception)~~terms ~~through~~and tofeatures ~~October~~must 31be and were bundled together and fair valued as a single, ~~2018:~~compound embedded derivative. Additionally, the warrants required classification as derivative liabilities.

The financings giving rise to derivative financial instruments and the income effects:	Three Months Ended December 31, 2013
Compound embedded derivative	$	(31,175	)
Derivative warrants		(11,568	)
Day-one derivative loss		(260,917	)
Total gain (loss)	$	(303,660	)

Based on the previous conclusions, the Company allocated the cash proceeds first to the derivative components at its fair value with the residual allocated to the host debt contract, as follows:

The Company’s face value $300,000 Secured Convertible Promissory Note and Detachable Warrants issued on October 3, 2018 gave rise to derivative financial instruments. The Notes embodied certain terms and conditions that were not clearly and closely related to the host debt agreement in terms of economic risks and characteristics. These terms and features consist of the embedded conversion option. Additionally the detachable warrants contained terms and features that gave rise to derivative liability classification.

	Allocation
Compound embedded derivative	$	321,631
Derivative warrants		85,183
Day-one derivative loss		(268,814	)
Financing fees		(13,800	)
Net proceeds	$	(124,200	)

The net proceeds of $124,200 were allocated to the compound embedded derivative and derivative warrants. This resulted in a day-one derivative loss of $268,814. Due to the 100% discount of the note, the net carrying value on the balance sheet was zero upon inception. The Note will be amortized up to its face value of $150,000 over the life of Note based on an effective interest rate. Amortization expense for the period amounted to $6,896. The carrying value of the Note as of April 30, 2019 amounted to $11,052.

F-13

APOTHECA BIOSCIENCES, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED APRIL 30, 2019

Accounting Considerations

The Company has accounted for the Note as a financing transaction, wherein the net proceeds that were received were allocated to the financial instrument issued. Prior to making the accounting allocation, the Company evaluated the agreement under ASC 815 Derivatives and Hedging (“ASC 815”). ASC 815 generally requires the analysis embedded terms and features that have characteristics of derivatives to be evaluated for bifurcation and separate accounting in instances where their economic risks and characteristics are not clearly and closely related to the risks of the host contract. The material embedded derivative feature consists of the embedded default puts. Because the conversion option is fixed and the agreements do not contain down-round protection, the debt met the definition of conventional convertible. However, the default put bears risks of equity which were not clearly and closely related to the host debt agreement and required bifurcation. Additionally, the warrants required classification as derivative liabilities due to the fundamental transaction provision.

Based on the previous conclusions, the Company allocated the cash proceeds first to the derivative components at its fair value with the residual allocated to the host debt contract, as follows:

	Allocation
Default put derivative	$	54,097
Derivative warrants		46,665
Convertible notes payable		49,238
Net proceeds	$	(150,000	)

The net proceeds of $150,000 were allocated to the default put derivative, derivative warrants and the residual allocated to the debt. The Note will be amortized up to its face value of $165,000 over the life of Note based on an effective interest rate. Amortization expense for the period amounted to $10,995. The carrying value of the Note as of April 30, 2019 amounted to $60,233.

Accounting Considerations

The Company has accounted for the Note as a financing transaction, wherein the net proceeds that were received were allocated to the financial instrument issued. Prior to making the accounting allocation, the Company evaluated the agreement under ASC 815 Derivatives and Hedging (“ASC 815”). ASC 815 generally requires the analysis embedded terms and features that have characteristics of derivatives to be evaluated for bifurcation and separate accounting in instances where their economic risks and characteristics are not clearly and closely related to the risks of the host contract. The material embedded derivative feature consists of the embedded default puts. Because the conversion option is fixed and the agreements do not contain down-round protection, the debt met the definition of conventional convertible. However, the default put bears risks of equity which were not clearly and closely related to the host debt agreement and required bifurcation.

F-14

APOTHECA BIOSCIENCES, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED APRIL 30, 2019

Based on the previous conclusions, the Company allocated the cash proceeds first to the derivative components at its fair value with the residual allocated to the host debt contract, as follows:

	Allocation
Default put derivative	$	65,224
Beneficial conversion feature		8,485
Convertible notes payable		31,290
Net proceeds	$	(105,000	)

The net proceeds of $105,000 were allocated to the default put derivative, beneficial conversion feature and the residual allocated to the debt. The Note will be amortized up to its face value of $105,000 over the life of Note based on an effective interest rate. Amortization expense for the period amounted to $7,609. The carrying value of the Note as of April 30, 2019 amounted to $38,899.

April 22, 2019 Note – JSJ Investments

On April 22, 2019, the Company entered into a Convertible Promissory Note Agreement with JSJ Investments in the aggregate principal amount of $113,000. The Company received net proceeds of $100,000 after a $10,000 in finders’ fees and $3,000 in legal expenses. The Note has a maturity date of April 22, 2020 and the Company has agreed to pay interest on the unpaid principal balance of the Note at the rate of five percent (5%) per annum from the date on which the Note is issued until the same becomes due and payable, whether at maturity or upon acceleration or by prepayment or otherwise. The Company shall have the right to prepay the Note, provided it makes a payment to JSJ Investments as set forth in the Note.

The outstanding principal amount of the Note is convertible at the lender’s option after the 180th day after the Issuance date a 50% discount to the lowest trading price during the previous ten (10) trading days to the date of a Conversion Notice.

Accounting Considerations

Based on the previous conclusions, the Company allocated the cash proceeds first to the derivative components at its fair value with the residual allocated to the host debt contract, as follows:

	Allocation
Embedded conversion feature	$	241,764
Day-one derivative loss		(128,764	)
Net proceeds	$	(113,000	)

The net proceeds of $113,000 were allocated to the embedded conversion feature. This resulted in a day-one derivative loss of $128,764. Due to the 100% discount of the note, the net carrying value on the balance sheet was zero upon inception. The Note will be amortized up to its face value of $113,000 over the life of Note based on an effective interest rate. Amortization expense for the period amounted to $3,054. The carrying value of the Note as of April 30, 2019 amounted to $3,054.

F-15

APOTHECA BIOSCIENCES, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED APRIL 30, 2019

NOTE 12 –DERIVATIVE FINANCIAL INSTRUMENTS

The following tables summarize the components of the Company’s derivative liabilities and linked common shares as of April 30, 2019 and January 31, 2019 and the amounts that were reflected in income related to derivatives for the period ended:

	April 30, 2019
The financings giving rise to derivative financial instruments	Indexed Shares		Fair Values
Compound embedded derivative		1,831,913	$	(277,069	)
Embedded conversion feature		1,614,286		(147,149	)
Default put derivative		3,100,418		(103,268	)
Derivative warrants		1,170,000		(129,450	)
Total		7,716,616	$	(656,936	)

The following table summarizes the effects on the Company’s gain (loss) associated with changes in the fair values of the derivative financial instruments by type of financing for the three months ended April 30, 2019:

The financings giving rise to derivative financial instruments and the income effects:
Combined derivatives	$	531,084
Day-one derivative loss		(128,764	)
Total gain (loss)	$	402,320

The Company’s Secured Convertible Promissory Notes and Detachable Warrants issued on October 3, 2018, January 18, 2019, March 19, 2019, April 22, 2019 and April 26, 2019 gave rise to derivative financial instruments. The Notes embodied certain terms and conditions that were not clearly and closely related to the host debt agreement in terms of economic risks and characteristics. These terms and features consist of the embedded conversion option. Additionally the detachable warrants contained terms and features that gave rise to derivative liability classification.

Current accounting principles that are provided in ASC 815 - Derivatives and Hedging require derivative financial instruments to be classified in liabilities and carried at fair value with changes recorded in income. In addition, the standards do not permit an issuer to account separately for individual derivative terms and features embedded in hybrid financial instruments that require bifurcation and liability classification as derivative financial instruments. Rather, such terms and features must be bundled together and fair valued as a single, compound embedded derivative. The Company has selected the Monte Carlo Simulations valuation technique to fair value the compound embedded derivative because it believes that this technique is reflective of all significant assumption types, and ranges of assumption inputs, that market participants would likely consider in transactions involving compound embedded derivatives. Such assumptions include, among other inputs, interest risk assumptions, credit risk assumptions and redemption behaviors in addition to traditional inputs for option models such as market trading volatility and risk-free rates. The Monte Carlo Simulations technique is a level three valuation technique because it requires the development of significant internal assumptions in addition to observable market indicators.

Significant inputs and results arising from the Monte Carlo Simulations process are as follows for the ~~compound~~ embedded ~~derivative~~derivatives that ~~has~~have been bifurcated from the Convertible Notes and classified in liabilities:

	Inception	October 31, 2018
Quoted market price on valuation date	$0.41	$0.44
Contractual conversion rate	$0.20	$0.20
Contractual term to maturity	1.00 Year	0.92 Years
Market volatility:
Equivalent Volatility	163.10%	152.57%
Interest rate	5.0%	5.0%

F-16

The Company has selected the Black Scholes Merton valuation technique to fair value the detachable warrants because it believes that this technique is reflective of all significant assumption types, and ranges of assumption inputs, that market participants would likely consider in transactions involving compound embedded derivatives.

APOTHECA BIOSCIENCES, INC.

NOTES TO THE ~~UNAUDITED~~ CONDENSED CONSOLIDATED ~~FINANCIAL~~ FINANCIAL STATEMENTS

FOR THE ~~PERIOD FROM~~THREE ~~FEBRUARY~~MONTHS ~~26,~~ENDED ~~2018,~~APRIL ~~(INCEPTION) THROUGH OCTOBER 31~~30, ~~2018~~ 2019

NOTE 10 –DERIVATIVE FINANCIAL INSTRUMENTS (CONTINUED)

	October 3, 2018 Note
	Inception	April 30, 2019
Quoted market price on valuation date	$0.41	$0.137
Contractual conversion rate	$0.20	$0.0687
Contractual term to maturity	1.00 Year	0.43 Years
Market volatility:
Equivalent Volatility	163.10%	231.81%
Interest rate	5.0%	5.50%

	January 18, 2019 Note
	Inception	April 30, 2019
Quoted market price on valuation date	$0.39	$0.137
Contractual conversion rate	$0.15	$0.0687
Contractual term to maturity	1.00 Year	0.72 Years
Market volatility:
Equivalent Volatility	195.42%	225.90%
Interest rate	5.0%	5.57%

	March 19, 2019 Note
	Inception	April 30, 2019
Quoted market price on valuation date	$0.126	$0.137
Contractual conversion rate	$0.0878	$0.0910
Contractual term to maturity	0.50 Year	0.39 Years
Market volatility:
Equivalent Volatility	200.2%	215.89%
Interest rate	5.50%	5.50%

	April 22, 2019 Note
	Inception	April 30, 2019
Quoted market price on valuation date	$0.20	$0.137
Contractual conversion rate	$0.07	$0.07
Contractual term to maturity	1.00 Year	0.98 Years
Market volatility:
Equivalent Volatility	218.49%	219.58%
Interest rate	5.50%	5.50%

	April 26, 2019 Note
	Inception	April 30, 2019
Quoted market price on valuation date	$0.1820	$0.137
Contractual conversion rate	$0.091	$0.091
Contractual term to maturity	0.49 Years	0.49 Years
Market volatility:
Equivalent Volatility	227.31%	237.78%
Interest rate	5.50%	5.50%

F-17

APOTHECA BIOSCIENCES, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED APRIL 30, 2019

Significant inputs and results arising from the Black Scholes Merton process are as follows for the detachable warrants classified in liabilities:

	Inception	~~October~~April 3130, ~~2018~~2019
Quoted market price on valuation date	$0.41	$0.441370
Contractual strike price	$0.3125	$0.3125
Range of effective contractual conversion rates	--	--
Contractual term to maturity	3.00 Year	2.9343 Years
Market volatility:
Volatility	166.14%	~~164~~173.7861%
Risk-free interest rate	2.94%	2.9359%

The following table reflects the issuances of compound embedded derivatives and detachable warrants and changes in fair value inputs and assumptions related to the compound embedded derivatives during the quarter ended October 31, 2018.

	Inception	April 30, 2019
Quoted market price on valuation date	$0.39	$0.1370
Contractual strike price	$0.3125	$0.3125
Range of effective contractual conversion rates	--	--
Contractual term to maturity	3.00 Year	2.72 Years
Market volatility:
Volatility	180.02%	179.55%
Risk-free interest rate	2.94%	2.59%

		October 31, 2018
	Inception March 19, 2019	April 30, 2019
Balances at February 26, 2018 (Company Inception)		$	--
Quoted market price on valuation date	$0.1260	$0.1370
Issuances:
Contractual strike price	$0.3125	$0.3125
Compound embedded derivative			408,373
Range of effective contractual conversion rates	--	--
Detachable warrants			128,544
Contractual term to maturity	3.00 Year	2.88 Years
Changes in fair value inputs and assumptions reflected in income			42,743
Market volatility:
Balances at October 31		$	579,660
Volatility	180.02%	179.55%
Risk-free interest rate	2.94%	2.59%

~~NOTE~~The 11following ~~–LEASE~~table ~~OBLIGATION~~reflects the issuances of compound embedded derivatives and detachable warrants and changes in fair value inputs and assumptions related to the compound embedded derivatives during the period ended April 30, 2019.

On August 1, 2018, the Company entered into a lease agreement with Nuvus Gro Corp, a related party. The agreement provides for monthly rent payments in the amount of $6,408. The lease period is 24 months. Upon execution of the agreement, the Company was required to pay the last month’s rent deposit in the amount of $6,000. As of October 31, 2018, the Company recorded $19,224 in rent expense related to this agreement. The Companies remaining lease obligation is as follows:

	April 30, 2019
Balances at February 1, 2019	$ 771,918
Issuances:
Embedded derivatives	361,085
Detachable warrants	46,665
Changes in fair value inputs and assumptions reflected in income	(522,732)
Balances at April 30, 2019	$ 656,936

Period		Amount Due
	Fiscal Year Ended January 31, 2019	$	19,224
	Fiscal Year Ended January 31, 2020		44,856
	Total	$	64,080

F-18

NOTE 1213 ~~–COMMON~~- ~~SHARES~~OPERATING TOLEASE BEAND ~~ISSUED~~RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES

~~From~~Operating ~~inception~~lease ~~through~~right-of-use ~~October~~assets ~~31,~~and ~~2018,~~liabilities are recognized at the present value of the future lease payments at the lease commencement date. The interest rate used to determine ~~Company~~the ~~received~~present ~~cash~~value ~~totaling~~is ~~$73~~our incremental borrowing rate,~~700~~ inestimated ~~exchange~~to ~~for~~be ~~184~~6%,~~250~~ ~~shares~~as the interest rate implicit in most of ~~common~~our ~~stock~~leases atis not $0readily determinable.40 ~~per~~Operating ~~share.~~lease Asexpense ofis ~~October~~recognized ~~31,~~on ~~2018 the~~a ~~shares~~straight-line ~~had~~basis ~~not~~over ~~been~~the ~~issued~~lease term. AsDuring ~~such~~the three months ended April 30, 2019, the ~~value~~Company ofrecorded $7327,~~700~~768, ~~was~~respectively ~~recorded~~as inoperating ~~equity~~lease ~~under~~expense ~~shares~~which tois beincluded ~~issued,~~in ~~common~~rent ~~shares~~expenses on the statements of operations.

~~NOTE~~We 13currently ~~–EQUITY~~sublease approximately 7,500 square feet of office space at 10901 Roosevelt Blvd, bldg. C, Suite 1000, Saint Petersburg, FL 33716, at $9,612 per month on a three-year lease from a related party, Nuvus Gro Corp. The agreement provides for monthly rent payments in the amount of $6,408. The lease period is 24 months. Upon execution of the agreement, the Company was required to pay the last month’s rent deposit in the amount of $6,000. As of January 31, 2019, the Company recorded $38,448 in rent expense related to this agreement. As of April 1, 2019, the agreement was modified to increase the monthly rent to $9,612.

In adopting ASC Topic 842, Leases (Topic 842), the Company has elected the ‘package of practical expedients’, which permit it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. The Company did not elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter is not applicable to the Company. In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of 12 month or less. On February 1, 2019, upon adoption of ASC Topic 842, the Company recorded right-of-use assets and lease liabilities of $158,704.

Right-of- use assets are summarized below:


	April 30, 2019
Office lease (remaining lease term of 15 months)	$158,705
Less accumulated amortization	(24,895)
Right-of-use assets, net	$133,810

Amortization on the right -of -use asset is included in rent expense on the statements of operations.

Operating Lease liabilities are summarized below:

	April 30, 2019
Office lease	$139,150
Less: current portion	(30,560)
Long term portion	$108,591

Maturity of lease liabilities are as follows:

Nine months ended April 30, 2019	$115,344
Year ending 2020	28,836
Less: Present value discount	(7,150)
Lease liability	$137,030

F-19

APOTHECA BIOSCIENCES, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED APRIL 30, 2019

NOTE 14 –COMMON SHARES TO BE ISSUED

From inception through April 30, 2019, the Company received cash totaling $73,700 in exchange for 184,250 shares of common stock at $0.40 per share. As of April 30, 2019 the shares had not been issued. As such, the value of $73,700 was recorded in equity under shares to be issued, common shares.

On April 30, 2019, the Company received a conversion notice of $20,000 convertible into 304,515 shares. The shares were not issued into May 6, 2019. The amount recorded into common shares to be issued for this transaction was $16,844.

NOTE 15 – OPTIONS

In connection with Employment Agreements executed on November 6, 2018, 1,000,000 options have been granted to the Company’s three current officers. The aggregate amount of options granted amounted to 3,000,000. The options have an exercise price of $0.31 per share and vest over three years. The Company calculated a grant date fair value of $560,953. From the period of inception (February 26, 2019) to April 30, 2019, the Company recorded $79,060 related the portion vested.

NOTE 16 –EQUITY

Common Stock

The Company has authorized 600,000,000 common shares with a par value of $0.001 per share. Each common share entitles the holder to one vote, in person or proxy, on any matter on which action of the stockholders of the corporation is sought.

AsOn ofNovember ~~October 31~~19, 2018, the company ~~had~~issued ~~113~~300,~~914,~~000 shares ofas ~~common~~a stock ~~issued~~bonus ~~and~~to ~~outstanding~~the Company’s CEO valued at $0.7080 per share, resulting in stock compensation expense of $212,400.

~~NOTE~~On 14December -20, ~~SUBSEQUENT~~2018, ~~EVENTS~~the company issued 4,000,000 shares as a stock bonus to the Company’s executives valued at $0.38 per share, resulting in stock compensation expense of $1,520,000.

On April 4, 2019, the Company issued 200,000 shares to the Company’s COO as compensation.

On April 4, 2019, the Company issued 200,000 shares to the Company’s CTO as compensation.

On April 4, 2019, the Company issued 50,000 shares to a related party (a relative of the CEO), in lieu of payment of $7,980 owed for marketing and design services.

On April 25, 2019 the Company issued 176,795 shares to FirstFire Global for conversion of $15,000 of principal.

NOTE 17 – RELATED PARTIES

Related parties are natural persons or other entities that have the ability, directly or indirectly, to control another party or exercise significant influence over the party in making financial and operating decisions. Related parties include other parties that are subject to common control or that are subject to common significant influences.

Fixed Assets

The Company purchased nine cubicles and nine office chairs amounting to $2,508 from Nuvus Gro Corp, which is a related party. This is classified in furniture and fixtures.

F-20

APOTHECA BIOSCIENCES, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED APRIL 30, 2019

Lease Agreement

On August 1, 2018, the Company entered into a lease agreement with Nuvus Gro Corp, a related party. The agreement provides for monthly rent payments in the amount of $6,408. The lease period is 24 months. Upon execution of the agreement, the Company was required to pay the last month’s rent deposit in the amount of $6,000. As of April 1, 2019, the agreement was modified to increase the monthly rent to $9,612. See Note 13.

Accounts Payable

As of April 30, 2019 and January 31, 2019, the Company had $16,020 and $8,225 in outstanding accounts payable to related parties, respectively. The company had a balance of $8,000 owed to the CEO’s wife, for product design and marketing services, of which $7,980 was converted into 50,000 shares of common stock. Additionally, the Company has a balance of $225 owed to Nuvus Gro Corp, a related party for the purchase of office furniture.

Related Party Advances -24,050

The Company received advances from related parties during the three months ended April 30, 2019. As of April 30, 2019, the Company had a balance due to Blockscience Corp, a related party, in the amount of $4,784. As of April 30, the Company had a balance due to Sam Talari, a related party, in the amount of $19,266. The company imputed interest on these advances in the amount of $218.

NOTE 18 – CONTINGENCIES

None.

NOTE 19 - SUBSEQUENT EVENTS

Management has evaluated events that occurred subsequent to the end of the reporting period shown herein:

Share issuances

~~Subsequent~~On toMay ~~the reporting period~~6, 2019 the Company issued ~~300~~304,~~000~~515 shares to ~~its~~FirstFire ~~President~~Global ~~Sam~~for ~~Talari~~conversion ~~for~~of a$20,000 ~~bonus~~of principal.

15On May 28, 2019 the Company issued 466,666 shares to FirstFire Global for conversion of $20,000 of principal.

On June 3, 2019, the Company issued 60,000,000 shares to Apotheca Biosciences LLC in connection with the Stock Purchase Agreement discussed in Note 6.

F-21

Item 2.

Management's Discussion and Analysis of Financial Condition or Plan of Operation

FORWARD-LOOKING STATEMENTS

This quarterly report contains forward-looking statements. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

Our unaudited financial statements are stated in United States Dollars (US$) and are prepared in accordance with United States Generally Accepted Accounting Principles. The following discussion should be read in conjunction with our financial statements and the related notes that appear elsewhere in this quarterly report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed below and elsewhere in this quarterly report.

Unless otherwise specified in this quarterly report, all dollar amounts are expressed in United States dollars and all references to “common stock” refer to shares of our common stock.

As used in this quarterly report, the terms “we”, “us”, “our company”, mean Cannabis Leaf Incorporated, a Nevada corporation, unless otherwise indicated.

Corporate Overview

Apotheca is a developer of cutting-edge medical products, nutraceuticals, formulation and delivery technologies for the healthcare and consumer care industry. Its pipeline of products includes, transdermal, sublingual, and nasal delivery technologies for precise and controlled dosing of cannabinoids. Apotheca believes that it can deliver meaningful benefits using its technologies to the world's aging population.

~~Apotheca~~The ~~Biosciences, Inc. (the "~~Company~~") was~~ originally was incorporated in ~~the State of~~ Nevada on October 6, 2014, under the name Pacificorp Holdings, Ltd. OnUntil ~~June 2~~2017, ~~2017 the~~we ~~Company~~were ~~entered into~~ a ~~short~~mineral ~~form~~exploration ~~Merger~~company ~~Agreement~~ with ~~the Company’s wholly owned subsidiary in order to effect the~~mining ~~change~~claims ofknown ~~their~~as ~~corporate name. The name change was effected through a parent/subsidiary short-form merger of~~ the ~~Company~~Delcer ~~and~~Buttes ~~its wholly~~(1-~~owned~~12) ~~subsidiary,~~in ~~Cannabis~~Elko ~~Leaf Incorporated.~~County, a Nevada ~~Corporation (the “Subsidiary”), under Section 92A~~.~~180 of~~ ~~the~~On ~~Nevada~~August ~~Revised Statutes (“NRS”). Pursuant to an Agreement of Merger~~31, ~~dated June 2,~~ 2017, ~~between~~we ~~the~~elected ~~Company and~~to ~~the~~not ~~Subsidiary,~~renew ~~effective June 7, 2017,~~ the ~~Subsidiary~~Delcer ~~merged~~Buttes claims ~~with~~ and ~~into~~subsequently, the ~~Company~~claims ~~and~~reverted ~~ceased~~back to ~~exist (~~the ~~“Merger”). Pacificorp~~Bureau ~~Holdings, Ltd was the surviving entity and adopted the name~~ of ~~the~~Land ~~subsidiary, Cannabis Leaf Incorporated~~Management.

16On March 29, 2017, we entered into a Letter of Intent with Affordable Green Washington LLC of Tacoma WA to obtain an exclusive license to market and distribute Affordable Green’s Products in the State of Washington.

On May 4, 2017, we entered into an exclusive License Agreement with Affordable Green Washington LLC. The License Agreement was amended on June 1, 2017.

On June 2, 2017, our company entered into a short form Merger Agreement with our wholly owned subsidiary, Cannabis Leaf Incorporated, in order to effect a change of name of our company. Pursuant to the Merger Agreement, our company will be the surviving entity and will adopt the name of our subsidiary. Our subsidiary was incorporated solely for the purpose of the merger. Effective June 7, 2017, Articles of Merger and the Merger Agreement were filed with the Nevada Secretary of State, giving effect to the merger and the change of name of our company to Cannabis Leaf Incorporated. The Merger was approved by our board of directors and our subsidiary on June 2, 2017. In accordance with Nevada Revised Statutes (NRS) Section 92A.180, stockholder approval was not required.

On April 26, 2018 our company provided a Notice of Termination to Green Venture with respect to the Letter of Intent entered into by our company and Green Venture on October 24, 2017. No Consideration has been paid to date.

On March 6, 2018, an Agreement for Plan of Merger (the “Agreement”) was entered into by our company and Apotheca Biosciences, Inc. (“Apotheca Biosciences”), a Nevada corporation. Such Agreement will result in the merger of Apotheca Biosciences into our company with our company to be the surviving entity under the name "Apotheca Biosciences, Inc.".

Pursuant to the Agreement, our company agreed to issue to Apotheca Biosciences sixty million (60,000,000) shares of our common stock in exchange for all of the shares of Apotheca Biosciences. This issuance will result in a change in control of our company. Upon execution of the Agreement, Apotheca Biosciences will receive the immediate right to the appointment of the directors and officers to our company, with our current officer resigning his officer positions. On April 24, 2018 our company issued 60,000,000 restricted common shares as the consideration under the Agreement.

On March 20, 2018 our company issued 831,330 and 142,670 restricted common shares in settlement of debt in the amounts of $166, 266 and $28,534 respectively.

On May 3, 2018 our company executed a Settlement and Release Agreement with Affordable Green Washington LLC (aka AGH WA, LLC) (the "Settlement Agreement") in order to terminate an Amended License Agreement dated June 1, 2017, cease the business relationship between the parties and remedy any defaults of the terms and conditions of the License Agreement. The compensation and settlement pertaining to Settlement Agreement is an aggregate total of 2,600,000 restricted common shares.

Effective August 2, 2018, Articles of Merger and the Merger Agreement were filed with the Nevada Secretary of State, giving effect to the merger and the change of name of our company to Apotheca Biosciences Incorporated. The Merger was approved by our board of directors and our subsidiary on March 31, 2018. In accordance with Nevada Revised Statutes (NRS) Section 92A.180, stockholder approval was not required.

We have not ever declared bankruptcy, been in receivership, or involved in any kind of legal proceeding. We have minimal revenues and limited cash on hand. We have sustained losses since inception and have relied solely upon the sale of our securities for funding.

Business of the Company

Upon the completion of the Agreement with Apotheca Biosciences, we are now a company that develops cutting-edge medical products and nutraceuticals and formulates and delivers technologies for the healthcare and consumer care industry. Our pipeline of products includes, transdermal, sublingual, and nasal delivery technologies for precise and controlled dosing of cannabinoids.

17Results of Operations

~~Results~~The following information represents our results of ~~Operations~~operations ~~For~~for ~~the~~three ~~Period~~months ~~from~~ ended April 30, 2019 compared to February 26, 2018 (Inception) through ~~October~~April 3130, 2018.

For the period from February 26, 2018, (inception) through October 31, 2018, the Company had no revenues. For the same period, we had $120,000 in personnel expenses and $127,984 in general and administrative expenses. We had $9,695 in interest expense resulting from accrued interest on notes payable and amortization of debt discount. For the period, we recorded a gain on settlement of liability in the amount of $156,000. Finally, for the period, we recorded derivative expense in the amount of $303,660. The net loss for the period amounted to $405,339.6

~~Results~~Three ofMonths ~~Operations~~Ended ~~For~~April ~~the~~30, ~~three months~~2019 ~~ended~~Compared ~~October~~to 31February 26, 2018 (Inception) through April 30, 2018

For the period from February 26, 2018, (inception) through October 31, 2018, the Company had no revenues. For the same period, we had $45,000 in personnel expenses and $110,763 in general and administrative expenses. We had $9,695 in interest expense resulting from accrued interest on notes payable and amortization of debt discount. For the period, we recorded a gain on settlement of liability in the amount of $156,000. Finally, for the period, we recorded derivative expense in the amount of $303,660. The net loss for the period amounted to $313,118.

Increase/(Decrease)							2019 vs. 2018
	2019			2018			$			%

Operating expenses:
Personnel expense	$	112,672		$	30,000		$	82,672			276	%
Marketing and design, related party		24,000			-			24,000			100	%
General and administrative		63,540			8,242			55,298			671	%
General and administrative, related party		35,268			-			35,268			100	%

Stock-based compensation		63,600			-			63,600			100	%
Total operating expenses	$	299,080		$	38,242		$	260,838			682	%

Net operating loss		(299,080	)		(38,242	)		(260,838	)		682	%

Other income (expense):
Interest expense		(71,818	)		-			(71,818	)		100	%
Interest expense, related party		(3,092	)		-			(3,092	)		100	%
Derivative income		371,349			-			371,349			100	%
Total other income (expense)		296,409			-			296,409			100	%

Net income (loss)	$	(2,671	)	$	(38,242	)		35,571			(93	%)

~~Liquidity and Capital Resources~~Revenue

~~For~~During the ~~period~~three months ended April 30, 2019 and from February 26, 2018, (~~inception~~Inception) through ~~October~~April 3130, 2018, ~~we have relied almost exclusively on funds raised from sales of shares of our common stock ,advances from related parties and~~ the ~~issuance~~Company ofhad ~~debt. We may need to raise additional capital to carry out our business plan. There can be~~ no ~~assurance that we will be able to raise additional capital or if we are able to raise additional capital that the terms will be acceptable to us~~revenues.

WeOperating ~~had cash on hand of $168,462 and $0.00 at October 31, 2018 and April 30, 2018, respectively. Our primary needs for cash are for working capital.~~Expenses

~~Working~~Personnel ~~Capital~~expenses

	October 31,		April 30,		Change
	2018		2018		Amount		%
Current Assets	$	174,462	$	-	$	-		-	%
Current Liabilities		695,374		32,242		488,670		(1516)	%
Working Deficiency	$	(530,912)	$	(32,242)	$	(488,670)		(1516)	%

Personnel expenses include expenses for payroll. We incurred personnel expenses of $112,672 for the three months ended April 30, 2019. From February 26, 2018 (Inception) through April 30, 2018 we incurred personnel expenses of $30,000. The increase of $82,672 was due to the hiring of new personnel in the period.

AsMarketing ~~of October 31, 2018, our company’s cash balance was $168,462~~ and ~~total assets were $174~~design,~~462.~~ Asrelated ~~of April 30, 2018, our company’s cash balance was $0.00 and total assets were $0.00.~~party

AsWe ofincurred ~~October~~marketing ~~31,~~and ~~2018,~~design ~~our~~expenses ~~company had total~~from ~~liabilities~~related parties of $~~695~~24,~~374~~000 ~~compared~~for ~~with~~the ~~total~~three ~~liabilities~~months ofended ~~$32~~April 30,~~242~~ 2019 as ofcompared to $0 for the period from February 26, 2018 (Inception) through April 30, 2018. The increase of $24,000 was due to payments made to a relative of the CEO for marketing services.

As of October 31, 2018, our company had working capital deficiency of $530,912 compared with working capital deficit of $32,242 as at April 30, 2018. The increase in working capital deficiency was primarily attributed to an increase in cash due to the issuance of a Convertible Note Payable, along with derivative liabilities arising from the Convertible Note transaction.7

18General and administrative expenses

~~Item~~General 3and administrative expenses include all costs associated with professional, legal fees, insurance, rent, dues, subscriptions, and other administrative expenses. ~~Quantitative~~We incurred general and ~~Qualitative~~administrative ~~Disclosures~~expenses ~~About~~of ~~Market~~$63,540 ~~Risk~~for the three months ended April 30, 2019 as compared to $8,242 for the period from February 26, 2018 (Inception) through April 30, 2018. The increase of $55,298 was due to the expansion of operations.

AsGeneral aand ~~“smaller~~administrative ~~reporting~~expenses ~~company”,~~– related ~~we are not required to provide the information required by this Item.~~parties

~~Item~~General 4and administrative expenses include all costs associated with professional, legal fees, insurance, rent, dues, subscriptions, and other administrative expenses paid to related parties. ~~Controls~~We incurred general and ~~Procedures~~administrative expenses from related parties of $35,268 for the three months ended April 30, 2019 as compared to $0 for the period from February 26, 2018 (Inception) through April 30, 2018.

~~Evaluation~~Stock ofbased ~~Disclosure Controls and Procedures~~compensation

~~Our~~We ~~management is responsible for establishing~~incurred ~~and~~stock-based ~~maintaining~~compensation aexpense ~~system~~ of disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) that is designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded$63,600 ~~processed,~~for ~~summarized and reported, within~~ the ~~time~~three ~~periods~~months ~~specified~~ended inApril ~~the Commission’s rules and forms. Disclosure controls and procedures include~~30, ~~without~~2019 ~~limitation,~~for ~~controls~~stock ~~and procedures~~bonuses ~~designed~~paid to ~~ensure that information required to be disclosed by an issuer in~~ the ~~reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer~~Company’s COO ~~management, including its principal executive officer or officers~~ and ~~principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure~~CTO.

AnOther ~~evaluation~~Income was conducted under the supervision and with the participation of our management of the effectiveness of the design and operation of our disclosure controls and procedures as of July 31, 2018. Based on that evaluation, our management concluded that our disclosure controls and procedures were not effective as of such date to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms as a result of the following material weaknesses: (Expense)

~~The~~Interest specific material weakness identified by our management was ineffective controls over certain aspects of the financial reporting process because of a lack of a sufficient complement of personnel with a level of accounting expertise and an adequate supervisory review structure that is commensurate with our financial reporting requirements and inadequate segregation of duties. A "material weakness" is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the company's annual or interim financial statements would not be prevented or detected on a timely basis.expense

We ~~expect~~incurred tointerest beexpense ~~materially~~of ~~dependent upon a~~$71,818 ~~third party to provide us with accounting consulting services~~ for the ~~foreseeable~~three ~~future.~~months ~~Until~~ended ~~such~~April ~~time~~30, 2019 as wecompared ~~have~~to a$0 ~~chief~~for ~~financial officer with~~ the ~~requisite~~period ~~expertise~~from inFebruary ~~U.S. GAAP~~26, ~~there~~2018 ~~are~~(Inception) nothrough ~~assurances~~April ~~that~~30, 2018. ~~the~~The ~~material~~increase ~~weaknesses~~ in ~~our~~interest ~~disclosure~~expense ~~controls and~~was ~~procedures~~related ~~and~~to ~~internal~~the ~~control~~amortization ~~over~~of ~~financial~~debt ~~reporting~~discount ~~will~~on ~~not~~convertible ~~result~~notes inand ~~errors~~accrued ~~in our financial statements which could~~interest ~~lead~~on tothe aconvertible ~~restatement of those financial statements~~notes.

~~Changes~~Interest inexpense ~~Internal~~– ~~Controls~~related parties

~~There~~We ~~have~~incurred ~~been~~interest noexpense ~~changes~~from ~~in our internal~~related ~~controls~~parties ~~over~~in ~~financial~~the ~~reporting~~amount ~~identified~~of in$3,092 ~~connection~~for ~~with~~ the ~~evaluation~~three ~~required~~months byended ~~paragraph~~April ~~(d)~~30, of2019 ~~Securities~~as ~~Exchange Act~~compared ~~Rule~~to ~~13a-15~~$0 orfor ~~Rule~~the ~~15d-15~~period ~~that~~from ~~occurred~~February in26, ~~the~~2018 (Inception) ~~quarter~~through ~~ended~~April ~~Aril~~ 30, 2018. ~~that~~The ~~have~~increase ~~materially~~in ~~affected,~~interest orexpense ~~are~~was ~~reasonably likely~~related to ~~materially~~the ~~affect,~~amortization ~~our~~of ~~internal~~the ~~control~~lease ~~over~~liability ~~financial~~due to ~~reporting~~a related party and imputed interest on related party advances.

19Derivative income

~~PART~~We IIrecorded -derivative ~~OTHER~~income ~~INFORMATION~~in the amount of $371,349 for the three months ended April 30, 2019 as compared to $0 for the period from February 26, 2018 (Inception) through April 30, 2018.

~~Item~~Net ~~1. Legal Proceedings~~Losses

We ~~know~~incurred ofa nonet ~~material,~~loss ~~existing~~of or$171 ~~pending~~for ~~legal~~the three ~~proceedings~~months ~~against~~ended ~~our~~April ~~Company~~30, ~~nor~~2019 ~~are we involved~~ as acompared ~~plaintiff~~to in$38,242 ~~any~~for ~~material~~the ~~proceeding~~period orfrom ~~pending~~February ~~litigation. There are no proceedings in which any of our directors~~26, ~~officers~~2018 or(Inception) ~~affiliates,~~through orApril ~~any registered beneficial shareholder~~30, is2018. The andecreased ~~adverse~~net ~~party~~loss orwas ~~has~~aided aby ~~material~~the ~~interest~~recording ~~adverse~~of toderivative ~~our interest~~income.

~~Item~~Current ~~1A.~~Liquidity ~~Risk~~and ~~Factors~~Capital Resources for the Three Months Ended April 30, 2019 Compared to February 26, 2018 (Inception) through April 30, 2018

As a "smaller reporting company", we are not required to provide the information required by this Item.



	2019		2018
Summary of Cash Flows:
Net cash (used) by operating activities		$ (105,673)		$ 296
Net cash provided by investing activities		(1,791)		-
Net cash provided by financing activities		355,000		-
Net decrease in cash and cash equivalents		247,536		296
Beginning cash and cash equivalents		2,942		-
Ending cash and cash equivalents		$ 250,478		$296

~~Item 2. Unregistered Sales of Equity Securities and Use of Proceeds~~8

Operating ~~None.~~Activities

~~Item~~Cash 3used in operations of $105,673 during the three months ended April 30, 2019 was primarily a result of our $2,671 net loss reconciled with our net non-cash expenses relating to depreciation expense, inventory, accounts payable and accrued liabilities. Cash ~~Defaults~~provided ~~Upon~~by ~~Senior~~operations ~~Securities~~of $296 for the period from February 26, 2018 (Inception) through April 30, 2018 was primarily a result of our $38,242 net loss reconciled with our net non-cash expenses relating to stock issued for services, accounts payable and accrued liabilities.

Investing ~~None.~~Activities

~~Item~~Net 4.cash ~~Mine~~used ~~Safety~~in ~~Disclosures~~investing activities for the three months ended April 30, 2019 resulted from the acquisition of furniture equipment in the amount of $1,791.

Financing ~~Not Applicable.~~Activities

~~Item~~Net 5.cash ~~Other~~provided ~~Information~~by financing activities was $355,000 for the three months ended April 30, 2019, which consisted completely of funds provided from convertible debt.

Future ~~None.~~Capital Requirements

20Our current available cash and cash equivalents are insufficient to satisfy our liquidity requirements. Our capital requirements for 2019 will depend on numerous factors, including management’s evaluation of the timing of projects to pursue. Subject to our ability to generate revenues and cash flow from operations and our ability to raise additional capital (including through possible joint ventures and/or partnerships), we expect to incur substantial expenditures to carry out our business plan, as well as costs associated with our capital raising efforts and being a public company.

~~Item~~Our 6.plans ~~Exhibits~~to finance our operations include seeking equity and debt financing, alliances or other partnership agreements, or other business transactions, that would generate sufficient resources to ensure continuation of our operations.

~~Item~~The 6sale of additional equity or debt securities may result in additional dilution to our shareholders. ~~Exhibits~~ If we raise additional funds through the issuance of debt securities or preferred stock, these securities could have rights senior to those of our common stock and could contain covenants that would restrict our operations. Any such required additional capital may not be available on reasonable terms, if at all. If we were unable to obtain additional financing, we may be required to reduce the scope of, delay or eliminate some or all of our planned activities and limit our operations which could have a material adverse effect on our business, financial condition and results of operations.

Exhibit Number	Description	Incorporated by Reference
		Form	Exhibit	Filing Date
(3)	(i) Articles of Incorporation (ii) Bylaws
3.1	Articles of Incorporation	S-1	3.1	April 21, 2015
3.2	By-laws	S-1	3.2	April 21, 2015
3.3	Articles of Merger	8-K	2.1	August 29, 2018
3.4	Agreement of Merger	8-K	2.1	August 29, 2018
3.5	Certificate of Change	8-K	3.2	August 29, 2018
14.1	Code of Ethics	S-1	14.1	April 21, 2015
31.1*	Section 302 Certification by the Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer
32.1**	Section 906 Certification by the Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

Inflation

*The ~~Filed~~amounts ~~herewith~~presented in our consolidated financial statements do not provide for the effect of inflation on our operations or financial position. The net operating losses shown would be greater than reported if the effects of inflation were reflected either by charging operations with amounts that represent replacement costs or by using other inflation adjustments.

** Furnished herewith9

21Item 3. Quantitative and Qualitative Disclosures About Market Risk

~~SIGNATURES~~ As a “smaller reporting company”, we are not required to provide the information required by this Item.

InItem ~~accordance~~4. ~~with~~Controls ~~Section~~and ~~13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.~~Procedures

		APOTHECA BIOSCIENCES, INC
		(Registrant)
Dated: December 19, 2018		/s/ Saeed Talari
		Saeed Talari
		President, Chief Executive Officer, Chief Financial Officer, Chairman and Director
		(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)

Evaluation of Disclosure Controls and Procedures

22Our management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) that is designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

An evaluation was conducted under the supervision and with the participation of our management of the effectiveness of the design and operation of our disclosure controls and procedures as of July 31, 2018. Based on that evaluation, our management concluded that our disclosure controls and procedures were not effective as of such date to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms as a result of the following material weaknesses:

The specific material weakness identified by our management was ineffective controls over certain aspects of the financial reporting process because of a lack of a sufficient complement of personnel with a level of accounting expertise and an adequate supervisory review structure that is commensurate with our financial reporting requirements and inadequate segregation of duties. A "material weakness" is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the company's annual or interim financial statements would not be prevented or detected on a timely basis.

We expect to be materially dependent upon a third party to provide us with accounting consulting services for the foreseeable future. Until such time as we have a chief financial officer with the requisite expertise in U.S. GAAP, there are no assurances that the material weaknesses in our disclosure controls and procedures and internal control over financial reporting will not result in errors in our financial statements which could lead to a restatement of those financial statements.

Changes in Internal Controls

There have been no changes in our internal controls over financial reporting identified in connection with the evaluation required by paragraph (d) of Securities Exchange Act Rule 13a-15 or Rule 15d-15 that occurred in the quarter ended Aril 30, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1.

Legal Proceedings

We know of no material, existing or pending legal proceedings against our Company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

Item 1A.

Risk Factors

As a “smaller reporting company”, we are not required to provide the information required by this Item.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3.

Defaults Upon Senior Securities

None.

Item 4.

Mine Safety Disclosures

Not Applicable.

Item 5.

Other Information

None.

Item 6.

Exhibits

Exhibit Number	Description	Incorporated by Reference
		Form	Exhibit	Filing Date
(3)	(i) Articles of Incorporation (ii) Bylaws
3.1	Articles of Incorporation	S-1	3.1	April 21, 2015
3.2	By-laws	S-1	3.2	April 21, 2015
3.3	Articles of Merger	8-K	2.1	August 29, 2018
3.4	Agreement of Merger	8-K	2.1	August 29, 2018
3.5	Certificate of Change	8-K	3.2	August 29, 2018
14.1	Code of Ethics	S-1	14.1	April 21, 2015
31.1*	Section 302 Certification by the Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer
32.1**	Section 906 Certification by the Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

* Filed herewith.

** Furnished herewith

SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		APOTHECA BIOSCIENCES, INC
		(Registrant)
Dated: June 19, 2019		/s/ P.C. Sundareswaran
		P.C. Sundareswaran
		President, Chief Executive Officer, Chief Financial Officer, Chairman and Director
		(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)

Filing Compare · Apotheca Biosciences, Inc.